Editor-On 10 December 2004 a banner headline on the front page of a popular tabloid newspaper read: "Cancer danger of folic acid" on the basis of a paper by Charles et al on taking folate in pregnancy and risk of maternal breast cancer.
1 2 Although coverage in the broadsheets was more balanced, the overall message would inevitably cause concern to women taking folate to reduce the risk of fetal neural tube defect in a desired pregnancy.
Despite the likelihood that the most likely explanation for the reported association is chance, as reported in the commentary to the paper, 2 numerous susceptible women will probably not take folate, and some of these may conceive fetuses with neural tube defects. In addition, what company or government will take responsibility for fortification of wheat and corn flour with folate, now that this question has been raised?
The authors themselves point out that the numbers are small and the confidence intervals large. The risk was also associated with a much larger dose of folate than is routinely used to reduce the risk of neural tube defects.
Those who write such papers and those who publish them cannot disclaim ethical responsibility for how the data are interpreted and must consider more carefully their ethical responsibilities in such situations. What's in a name?
Gordon Stirrat senior research fellow in ethics in
Editor-In their interesting follow up of an old trial, Charles et al tell us that this randomised trial was of high quality and that the trial was double blind. 1 They also tell us that tablets were supplied in six colours, two of which contained folate in 0.2 mg and 5 mg daily doses. The tablets were kept in numbered drawers and distributed in sequence.
If the tablets had different colours for different treatments the trial wasn't double blind, as any trialists seeing the tablets would know the treatment. If treatments were given sequentially they were not random. Also, there was no allocation concealment, an important indicator of high quality, if treatments were given sequentially, as the treatment for the next subject would be known. I would not criticise the authors because a trial carried out in the 1960s does not meet current standards, but we should use technical terms such as double blind and randomised to mean what it is agreed that they mean, not something else.
Another curiosity of their report is that there seem to be four times as many subjects receiving placebo as receiving either active treatment. I cannot get access to the original paper, but this seems a rather extravagant design, even for the 1960s. Were some of these "placebos" other treatments? If so, is it possible that these other treatments could reduce the risk of death, rather than folate increasing it?
There are 30 tests of significance here, including the confidence intervals. One is significant at the 0.05 level, P = 0.02. A simple Bonferroni correction would show that the P value for the composite hypothesis that folate increases risk of death is 30 times 0.02 = 0.6. The authors do not tell us why of all the possible causes of death they picked breast cancer; they tell us they had no prespecified hypothesis that taking folate supplements in pregnancy would increase the risk of cancer. One wonders how many other causes they looked at and which have not been mentioned. Of course, the Bonferroni method is crude and the tests are not independent, but in the absence of any more appropriate analysis by the authors it is all the reader can do.
Editor-We believe that we have behaved ethically. We emphasised the preliminary nature of our findings and submitted our paper as a research pointer. We worked with the press offices of our universities, the BMJ, and the Department of Health to promote responsible media coverage. The journalist working for the tabloid referred to by Stirrat did not speak to us.
Although we agree that media reporting of scientific articles might be improved, we do not think that suppression of research findings is justified. Greenland et al have argued empirical observations should be reported so that they can be used to develop and test theoretical understandings of disease aetiology.
1 It might be more appropriate to ask whether it is ethical not to conduct long term follow up of large randomised trials that produced immediate effects.
Participants in this trial were sequentially allocated to receive pills of different colours. Neither the investigator nor the subjects knew which colour was which. So, as folate does not produce any side effects that would lead the investigators to break the code, the treatment was concealed and this was a double blind trial. Although strictly speaking the allocation was not the same as random allocation, we used the term random because the process was essentially random. As Chalmers and Altman and Bland have pointed out, 2 3 sequential allocation should be unbiased providing concealment is adequate. As previously described there was no other treatment arm in this trial and the assignment ratios were as specified. This could be confirmed by reading the paper that we referenced. 4 We are happy to send Bland a copy of this paper, but we note from the website of the library at his institution, the University of York, that the journal is available there.
We made it clear that our findings were not prespecified and agree that the P values should be interpreted with caution. 
Screening for abdominal aortic aneurysm

Headline is misleading
Editor-The front cover of the BMJ of 27 November declared that screening for aortic aneurysm does not reduce overall death rates. This headline misrepresents the conclusions of the study itself, 1 let alone evidence from the UK multicentre aneurysm screening study of 68 000 men, which showed that screening halves aneurysm related deaths by reducing risk of rupture. 2 The Australian trial studied 41 000 men aged 65-83, and the authors admit their target group was not suitable.
1
Half the men over 75 invited for screening did not attend and accounted for two thirds of deaths from aneurysm. Among those aged 65-74, not one patient died of aneurysm disease in 8641 men attending screening, compared with 11 deaths in non-attendees and 13 deaths in controls. The authors concluded that the chief reasons for their overall result seemed to have been their failure to identify and exclude men who were unlikely to attend, a substantial proportion being older than 75.
In Britain only suitable men aged 65-74 are invited by and scanned in general practitioners' surgeries. The Australians selected from electoral rolls and scanned people in specialised clinics. The Gloucestershire experience showed general practice based screening achieves 85% compliance, 3 compared with 63% in the Australian study. The lesson from Australia, acknowledged by the authors but not the headline, is that aneurysm screening programmes must be designed carefully and monitored rigorously to be effective. A recent survey from the Vascular Society shows national screening programmes for aortic aneurysm to be the highest priority for consultant vascular surgeons in the United Kingdom. 
Screening reduces deaths related to aneurysm
Editor-The Australian randomised trial of aortic aneurysm screening observed 18 deaths related to aneurysm in the group of men invited for screening and 25 in the control group. 1 The corresponding reduction in mortality was 39% (relative risk 0.61, 95% confidence interval 0.33 to 1.11), which the authors summarise as showing that screening did not reduce overall death rates. The authors have fallen into the common trap of interpreting a non-significant difference as evidence of no difference.
The stated conclusion is all the more surprising given the available evidence from other randomised trials (table) . In each trial, the number of aneurysm related deaths in the men invited for screening is lower than in the control group, and so the relative risks are all below 1. The widths of the confidence intervals vary according to the size and power of the trial. The largest trial, the multicentre aneurysm screening study (MASS), shows a significant benefit. 2 So does the Danish trial, based on the published aneurysm related mortality in hospital. 3 The Chichester and Australian trials, were too small to show the difference convincingly. 4 But it does not take a formal metaanalysis to deduce the high level of evidence, across the four trials, that screening reduces mortality related to aneurysm by the order of 40% (corresponding to a relative risk of 0.60). Speculation about possible reasons for the differences between the results of the trials is unhelpful, when what is more notable is their consistency. 
Authors' reply
See correction, p 596
Editor-We reported the study in a transparent fashion and were deliberately cautious in our conclusions. Australia and the United Kingdom are very different with regard to arrangements for primary care, which did not permit us to undertake a preliminary assessment of the eligibility of men for screening before we randomised them and issued half invitations to attend for the ultrasound examination. As such an assessment was possible in the British trials, direct comparison of response fractions between the studies undertaken in the two countries is not valid. In the Australian trial, the response to invitations was on a par with that for mammography screening, and there is good, population based evidence that the latter programme has had a clinically important impact on the presentation of breast cancer.
1
The MASS trial indicates that screening should be introduced in the United Kingdom. Our results should not undermine this. One of the reasons our discussion focused on differences between our trial and MASS was that the effectiveness of screening may vary according to healthcare setting. Our contention is that, having been generated in an importantly different setting, the Australian results can be used to support the case for establishment of carefully designed screening programmes.
We agree with Thompson et al that the totality of the available level 2 evidence is the minimum basis on which national policies on screening for abdominal aortic aneurysm should be set. This body of evidence sets a standard against which the often heard calls to establish screening programmes for other conditions should be judged. 
Most recent published results from the randomised trials of abdominal aortic aneurysm screening in men
Democratisation of scientific advice
Secrecy and democracy don't mix
Editor-Bal et al struggle to show that "concealing information from public scrutiny" is a necessary condition for "democratic function" but fail. 1 The fault in their argument is the assumption that an advisory committee should alone decide how the question is framed, how different types of evidence should be privileged, and how the "performance" should be presented. Similar debates have been vigorously pursued in the health impact assessment community.
Dissention in the scientific community is not a problem that should be hidden from an ignorant public but a fundamental mechanism in the advancement of knowledge. It is true that knowledge of temporary or continued dissention will be used naively or even mischievously and so confuse issues, but that is no excuse for hiding the process by which conclusions are reached.
Scientific reasoning is a powerful tool for improving public decision making, but it is not sufficient. Account has to be taken of lay knowledge. Experiential evidence, which covers far more than experience of disease, is one part of this. "Irrational" concerns (better described as differently rational) and values also have to be taken into account as do all the messy considerations of political possibility. That scientists should seek to avoid the complexity of wicked problems by retreating into secrecy is understandable, but benign paternalism is no answer to mature democratic making of public policy. 
Authors advocate getting dressed for public performance, not nakedness is bad
Editor-Rather than arguing that nakedness is bad like Abbasi, 1 in our article on the democratisation of science we urge transparency advocates to be specific about the body parts that should be displayed publicly. 2 As scientific advisory councils find themselves at the intersections of science and society, they necessarily transgress the boundaries of science. This makes them vulnerable to the politicisation of their work. Sound scientific advice is urgently needed in a time where our societies are overwhelmed with new technologies. Therefore, we think that science advisory boards do well in taking utmost care in shaping their relations with policy actors and the citizenry.
The experience of the Health Council of the Netherlands in dealing with scientific elements (colliding knowledge claims, etc), can be inspiring to develop methods and procedures to allow societal elements into the advisory process. 3 Transparency about one's arguments, allowing your readership to join you in (or dissent from) a line of reasoning, is one of these fragile new procedures that enables the council to be both scientific and useful to policy and public debate.
Scientific journals should publish dissenting voices, as this is important for the advancement of science (although journals also have their backstage processes, as McCabe says in her rapid response 4 ). Science advisory boards, however, are to advise government on the state of the art. Debates in the committee further that goal, as this is useful in mobilising the expertise of committee members. Confidentiality of the committee process is essential for the production of such debates (public scrutiny during the process might deter openness among experts). Whereas it goes without saying that lasting dissent is not to be concealed, it seems unwise to bring temporary dissent into the open, as this would be easily taken up to politicise the advice and thus render it ineffective. 
Charcoal burning is also popular for suicide pacts made on the internet
Editor-Rajagopal's editorial discussed how strangers can initiate suicide pacts on the internet. 1 The two cited Japanese suicide pacts both used a new suicide method, charcoal burning. These widely publicised pacts were followed by four additional pacts and 13 deaths in two months, all of whom used charcoal burning. The new suicide method entails smouldering barbecue coal in a small and sealed environment, such as a bedroom, with the aim of producing a carbon monoxide chamber in a short time. [2] [3] [4] In Hong Kong we had also observed that suicide pacts commonly used charcoal burning to institute death. Several characteristics of charcoal burning make it desirable for people who want to commit suicide together. Unlike other methods of suicide, such as jumping and hanging, it can easily be shared. Besides, charcoal burning is often portrayed as nondisfiguring and painless. Hence, passive partners in suicide pacts could be more easily lured into the act.
The internet, apart from connecting otherwise isolated anomies in forming suicide pacts in Japan, has played an important part in spreading the new suicide method across societies. Charcoal burning and cyber suicide pacts are examples of how globalisation and new technology are creating new challenges for global health.
Submission to multiple journals to reduce publication times
Idea needs further evaluation
Editor-Torgerson et al moot the idea of submission to multiple journals to reduce publication times, but their article raises more questions than it provides answers. 1 Firstly, to how many journals would authors be allowed to submit their article, and who will decide the number of simultaneous submissions-the authors or the journal?
Secondly, in the event of simultaneous acceptance by many journals, who would decide that the accepted article should remain with which journal-the authors (who always want their article published in the best journal) or the journals themselves (which might fight for the article if it is really high quality) ? Thirdly, what would happen to low rated journals (which may not be getting the article in first place)?
Fourthly, if the article were rejected by all the journals to which it was submitted, should the authors be allowed to resubmit it simultaneously to a couple of journalsagain wasting the time of the whole scientific community apart from journal resources?
Multiple submission may not be an ideal way to deal with the problem of delay until all the issues related to are resolved. It needs further evaluation before being enforced. One of the ways to reduce the time for publication is that, if a journal is about to reject an article it should be responsible for suggesting to the authors to which journal (two or three, in order of preference) they should send their article next. The suggestion should arise from review of the article by panel of experts on the subject, who would know for which journal the submitted article is most suitable and where it is most likely to be accepted.
